Centene, WellCare $17.3B merger clears regulatory requirements

Centene has passed all regulatory hurdles to seal the deal on a merger with WellCare Health Plans worth $17.3 billion.

Centene, a Fortune 100 company, is a multinational healthcare business that provides health plans and services. Tampa-based WellCare offers managed care plans through Medicaid, Medicare Advantage, Medicare Prescription Drug Plans and the individual marketplace. WellCare acquired the Medicare Part D prescription drug plan of Aetna in 2018 as part of Aetna’s $69 billion merger with CVS Health.

“We are pleased to achieve this milestone and look forward to closing our acquisition of WellCare and providing more members and communities access to high-quality healthcare," Michael F. Neidorff, Centene's chairman, president and CEO, said in a statement. "We also look forward to building on our relationships with providers and government partners through the combined company's wide range of affordable health solutions. We have been working diligently on the integration plans to bring our organizations together so that it is seamless for members, providers and employees of both companies."

The merger was approved by shareholders of both Centene and WellCare back in June 2019. All regulatory requirements have been met under the merger agreement as well as approval from the Department of Justice.

As part of the deal, WellCare will divest its Medicaid and Medicare Advantage Plans in Missouri and Medicaid plan in Nebraska. Centene will divest its Medicaid and Medicare Advantage plans in Illinois. The divestitures will occur on or about January 23, 2020, according to the announcement.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”